A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates

Journal of Virology

Volumn 74, Issue 21, 2000, Pages 10025-10033

  Verrier, F ^a   Burda, S ^a   Belshe, R ^a   Duliege, A M ^a   Excler, J L ^a   Klein, M ^a   Zolla Pazner, S ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ARTICLE; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCHEMISTRY; PRIORITY JOURNAL; VIRUS ISOLATION;

ADOLESCENT; ADULT; AIDS VACCINES; CROSS REACTIONS; FEMALE; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMAN; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGE; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; VACCINES, SYNTHETIC;

EID: 0033775496     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.21.10025-10033.2000     Document Type: Article

References (77)

1. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera
2. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys
3. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: An approach for HIV type 1 serological subtyping
4. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group
5. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network
6. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees
7. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251
8. The antibody response in HIV-1 infection
9. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage
10. Serotyping HIV type 1 by antibody binding to the V3 loop: Relationship to viral genotype
11. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus
12. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group
13. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
14. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy
15. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
16. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
17. The prime-boost concept applied to HIV preventive vaccines
18. Poliovirus neutralizing antibody persistence after vaccination with the Sabin vaccine: A follow-up study
19. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
20. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1
21. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120
22. Generation of human monoclonal antibodies to HIV
23. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and inter-clade cross-reactivity
24. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group
25. Serological responses to candidate AIDS vaccines
26. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network
27. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network
28. Measuring vaccine-induced HIV neutralization: Report of a workshop
29. Toward an understanding of the correlates of protective immunity to HIV infection
30. Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4
31. What level of hepatitis B antibody is protective?
32. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response
33. Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1
34. Improved antigenicity of the HIV env protein by cleavage site removal
35. Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1
36. Progress in the development of an HIV-1 vaccine
37. Cross-reactive antibodies induced by a monovalent influenza B virus vaccine
38. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization
39. Two antigenically distinct subtypes of HIV-1: Viral genotype predicts neutralization immunotype
40. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
41. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group
42. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development
43. Synthetic peptide ELISAs for detection of and discrimination between group M and group O HIV type 1 infection
44. Development of HIV-1 group-specific neutralizing antibodies after seroconversion
45. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
46. Neutralization of primary human immunodeficiency virus type 1 isolates: A study of parameters implicated in neutralization in vitro
47. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B
48. Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes
49. Mapping of epitopes exposed on intact HIV-1 virions: A new strategy for studying the immunologic relatedness of HIV-1
50. Multivariate analysis of human immunodeficiency virus type 1 neutralization data
51. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus
52. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site
53. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein
54. A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: Evidence for persistent cell-mediated immunity
55. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection
56. Extent of antigenic diversity in the V3 region of the surface glycoprotein gp120 of human immunodeficiency virus type 1 group M and consequences for serotyping
57. Hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum
58. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups
59. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus
60. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120
61. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine
62. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
63. Hepatitis B vaccine in medical staff of hemodialysis units: Efficacy and subtype cross-protection
64. Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge
65. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant
66. Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV
67. Protection of macaques against a SHIV with a homologous HIV-1 env and a pathogenic SHIV-89.6P with a heterologous env by vaccination with multiple gene-deleted SHIVs
68. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines
69. Characterization of a soluble oligomeric HIV-1 gp160/gp41 protein as a candidate subunit vaccine
70. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1
71. Neutralization serotypes of HIV-1 field isolates are not predicted by genetic subtype
72. A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS
73. Neutralization of a clade B primary isolate by sera from HIV-uninfected recipients of candidate AIDS vaccines
74. Immunotyping of human immunodeficiency virus type 1 (HIV): An approach to immunologic classification of HIV
75. Induction of neutralizing antibodies in T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees
76. Neutralization of syncytium-inducing primary isolates by sera from HIV-uninfected recipients of candidate HIV vaccines